← Leaderboards
Xiao-Kun Zhang
Molecular Medicine Research Institute
$10,104,205
Attributed
$10,104,205
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $977.4K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,104,205 · 8
By mechanism
R01$9,131,589 · 6
P01$512,440 · 1
R21$460,176 · 1
Top collaborators
No co-investigators on record.
Most similar at Molecular Medicine Research Institute
Same institution · by research overlap
- Marcia I. Dawson$4,173,024
- Mark E Leid$3,287,794
- Joseph A Fontana$2,820,744
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisNuclear ReceptorsPhosphorylationMitochondriaMediatingPathway InteractionsCancer CellProteinsMalignant NeoplasmsIn VitroBinding (Molecular Function)MolecularMemberPlaySignal TransductionSmall MoleculeBaseApoptoticCell NucleusSignal PathwayPublic Health RelevanceAnimalsCytoplasmNovel Therapeutics
Grant awards (29)
Nongenomic Coregulators of RXRalpha$432,680
R01 · FY2019 · CA · contact PI
Nongenomic Coregulators of RXRalpha$446,063
R01 · FY2018 · CA · contact PI
The Bcl-2-p85/PI3K signaling axis$380,712
R01 · FY2014 · CA · contact PI
Role of tRXRalpha in pancreatic cancer development and therapy$205,701
R21 · FY2014 · CA · contact PI
The Bcl-2-p85/PI3K signaling axis$368,938
R01 · FY2013 · CA · contact PI
Conversion of Bcl-2 by Orphan Nuclear Receptor Nur77$353,958
R01 · FY2013 · GM · contact PI
Role of tRXRalpha in pancreatic cancer development and therapy$254,475
R21 · FY2013 · CA · contact PI
The Bcl-2-p85/PI3K signaling axis$384,435
R01 · FY2012 · CA · contact PI
Conversion of Bcl-2 by Orphan Nuclear Receptor Nur77$359,271
R01 · FY2012 · GM · contact PI
The Bcl-2-p85/PI3K signaling axis$384,435
R01 · FY2011 · CA · contact PI
Conversion of Bcl-2 by Orphan Nuclear Receptor Nur77$359,271
R01 · FY2011 · GM · contact PI
The Bcl-2-p85/PI3K signaling axis$396,325
R01 · FY2010 · CA · contact PI
Conversion of Bcl-2 by Orphan Nuclear Receptor Nur77$362,900
R01 · FY2010 · GM · contact PI
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$119,956
R01 · FY2009 · CA · contact PI
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$474,814
R01 · FY2008 · CA · contact PI
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$455,425
R01 · FY2007 · CA · contact PI
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$461,754
R01 · FY2006 · CA · contact PI
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$452,745
R01 · FY2005 · CA
TR3/nur77 in Survival and Death of Cancer Cells$307,125
R01 · FY2005 · CA
15-Deoxy-D12, 14-PGE, J2 as a ligand of RXRalpha$462,309
R01 · FY2004 · CA
TR3/nur77 in Survival and Death of Cancer Cells$307,125
R01 · FY2004 · CA
TR3/nur77 in Survival and Death of Cancer Cells$307,125
R01 · FY2003 · CA
RETINOIC ACID RESPONSE IN HUMAN LUNG CANCER$322,574
R01 · FY2002 · CA
TR3/nur77 in Survival and Death of Cancer Cells$307,125
R01 · FY2002 · CA
MOLECULAR MECHANISM OF RETINOID ACTION$256,220
P01 · FY2002 · CA
RETINOIC ACID RESPONSE IN HUMAN LUNG CANCER$313,233
R01 · FY2001 · CA
TR3/nur77 in Survival and Death of Cancer Cells$307,125
R01 · FY2001 · CA
RETINOIC ACID RESPONSE IN HUMAN LUNG CANCER$304,166
R01 · FY2000 · CA
MOLECULAR MECHANISM OF RETINOID ACTION$256,220
P01 · FY2000 · CA